Latest Breaking News On - Advicenne inc - Page 1 : comparemela.com
Advicenne: Strong improvement of 2023 results thanks to sustained commercial activity on Sibnayal® -March 28, 2024 at 02:31 am EDT
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Advicenne: Strong improvement of 2023 results thanks to sustained commercial activity on Sibnayal
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Advicenne Reports its Full-Year Financial Results to December 31, 2020 and Confirms its 2021 Outlook
Regulatory News:
Advicenne (Paris:ADVIC) (BSE:ADVIC) (Euronext: ADVIC), a French company specialized in the development of therapeutic products adapted to children and adults for treating nephrological and neurological orphan diseases, today reported its 2020 financial results.
2020 HIGHLIGHTS
Scientific developments
On March 10, 2020, Advicenne was authorized to make ADV7103 available within the framework of a Temporary Authorization for Use (TAU) scheme established by France s National Agency of Medicine and Health Products Safety (
Agence nationale de sécurité du médicament et des produits de santé (ANSM)). This authorization allows the exceptional use of coated 8 mEq and 24 mEq granules in sachets for the treatment of distal renal tubular acidosis (dRTA) in France. Its prescription is reserved for physicians specializing in nephrology.
Advicenne Provides an Update as its Operations Evolve
Advicenne (Euronext: ADVIC) (Paris:ADVIC) (BSE:ADVIC) provides an update on the overall progress of the Company.
In Europe, with the recent positive CHMP Opinion for our lead medicine ADV7103-Sibnayal, Advicenne should receive the EMA Marketing Authorization (MAA) for Sibnayal soon. The company is currently pursuing discussions with several partners for its commercialization in most countries of the European Community.
Meanwhile the clinical program in cystinuria in the EU is progressing. In spite of the hurdles encountered due to the ongoing COVID-19 crisis, the submission for Marketing Authorization is expected by late 2022.